Alpha-Defensin vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | Alpha-Defensin | SS-31 (Elamipretide) |
|---|---|---|
| Dose Range | 100 mcg–500 mcg | 20 mg–40 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Various routes studied including topical, local injection, and systemic administration depending on application. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Limited human use data. May cause local inflammation. Potential for immune activation effects. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
Alpha-Defensin, SS-31 (Elamipretide) are both commonly used for:
Key Differences
Unique to Alpha-Defensin:
Unique to SS-31 (Elamipretide):
Which Has Stronger Evidence?
| Goal | Alpha-Defensin | SS-31 (Elamipretide) |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
Alpha-Defensin
- AhR Activation Transcriptionally Induces Anti-Microbial Peptide Alpha-Defensin 1 Leading to Reversal of Gut Microbiota Dysbiosis and Colitis.
Gut microbes, 2025
- Alpha-defensin binding expands human adenovirus tropism.
PLoS pathogens, 2024
- Alpha-Defensin 1: An Emerging Periodontitis Biomarker.
Diagnostics (Basel, Switzerland), 2023
SS-31 (Elamipretide)
- Elamipretide: First Approval.
Drugs, 2026
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Circulation. Heart failure, 2026
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Neurochemical research, 2026
Ready to Learn More?
Looking for trusted sources?